Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
IVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.53 - $4.05
Previous CloseN/A
Volume917.00
Average Volume (3M)16.77K
Market Cap
$448.73M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Sep 29, 2025EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding139,151,280
10 Day Avg. Volume19,328
30 Day Avg. Volume16,768
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$20.00Price Target Upside521.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's previous funding concerns were resolved with a significant financing, making it an appealing asset with blockbuster potential.
Partnership PotentialLanifibranor offers a very attractive opportunity in the MASH space, for investors as well as a partner.
Trial ProgressThe Phase III NATiV3 trial for lanifibranor has completed full enrollment and is on track to report Phase III top-line data, making it a compelling asset for partnering.
Bears Say
Funding ConditionsCompletion of enrollment in NATiV3 supports satisfaction of certain conditions related to the second tranche of approximately €116 million of structured financing.
Market CompetitionLanifibranor could become the second orally-dosed MASH therapy approved by the FDA, exhibiting a stronger efficacy profile compared to resmetirom.
Trial RiskManagement is highly confident in NATiV3 reaching the target of randomizing 969 patients into the main cohort, paving the way for the trial's top-line data readout.
Inventiva News
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $1.53 and its highest was $4.05 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $448.73M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Sep 29, 2025 which is in 57 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Mar 26, 2025. The company reported -$1.818 earnings per share for the quarter, missing the consensus estimate of -$0.559 by -$1.259.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.63.
How many shares outstanding does Inventiva have?
Inventiva has 139,151,280 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$1.818 in its last earnings report, missing expectations of -$0.559. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (521.12% Upside)
$20.00 (521.12% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 14.9%
Last 30 Days ▼ 14.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.47%
12-Months-Change
Fundamentals
Return on Equity
344.74%
Trailing 12-Months
Asset Growth
60.83%
Trailing 12-Months
Company Description
Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
IVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the clinical development of lanifibranor, positive trial results, and a strong financial position bolstered by recent financing activities. However, challenges such as workforce reduction and decreased revenue were noted. The sentiment remains cautiously optimistic with strategic partnerships and governance strengthening, despite financial and operational challenges.Read More>IVA Stock 12 Month Forecast
Average Price Target
$20.00
▲(521.12%Upside)
Technical Analysis
Oruka Therapeutics
―
Heron Therapeutics
―
RegenXBio
―
Verve Therapeutics
―
Entrada Therapeutics Inc
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
3.44% Other Institutional Investors
96.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---